Wikipedia

QazCovid-in

QazCovid-in, commercially known as QazVac,[1][2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.[3][4] QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.[5]

QazCovid-in
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Routes of
administration		Intramuscular
Identifiers
CAS Number
DrugBank

Manufacturing

edit

The vaccine can be stored at standard refrigeration temperatures (2 °C-8 °C) and is a two-dose régime with the doses administered twenty-one days apart.[6] The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.[citation needed]

Beginning in June 2021, the vaccine is slated[7] to be packaged in large bulk to be bottled in Turkey by a major Turkish company.[8] This will allow for a production capacity of 500,000-600,000 doses per month.[9] The contract is still being negotiated,[10] despite earlier claims suggesting that the deal had already been finalized.[11][12]

In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022.[13]

History

edit

Clinical trials

edit

In September 2020, QazVac started in Phase I/II clinical trials.[14]

In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021.[2][8] It is unclear when the first preliminary results will be published.[15][12]

The administration of the vaccine for the general population began at the end of April 2021.[16] The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high".[8]

In September 2021, a study was published to eClinicalMedicine, published by The Lancet. The study’s findings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.” [17]

Authorization

edit
See also: List of COVID-19 vaccine authorizations § QazCovid-in

Economics

edit

The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.[citation needed] In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.[18]

References

edit
  1. ^ Kumenov A (1 April 2021). "Kazakhstan: Officials under fire over vaccination failures". Eurasianet. Retrieved 11 April 2021.
  2. ^ a b Tatyana K (31 March 2021). "Vaccination with homegrown QazVac vaccine likely to start in late April". www.inform.kz. Retrieved 11 April 2021.[permanent dead link‍]
  3. ^ Yergaliyeva A (20 December 2020). "Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in". The Astana Times. Retrieved 2 March 2021.
  4. ^ Clinical trial number NCT04691908 for "Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine" at ClinicalTrials.gov
  5. ^ Arystanbek A. "Kazakh Biosafety Research Institute Begins Clinical Trials of Another Vaccine Against COVID-19". The Astana Times.
  6. ^ Tatyana K (26 April 2021). "Health Minister Alexei Tsoi to be one of the first to get homegrown QazCovid-in vaccine". www.inform.kz. Retrieved 26 April 2021.
  7. ^ It's unclear at which level of preparation the vaccine will be sent to Turkey.
  8. ^ a b c Akulova O, Gani T (9 April 2021). "QazVac готова и уже на подходе" [QazVac is ready and on the way]. Время [Time] (in Russian). Retrieved 11 April 2021.
  9. ^ Batyrov A (25 April 2021). "Kazakhstan Launches Production of First Homegrown Vaccine, 'QazVac'". caspiannews.com. Retrieved 26 April 2021.
  10. ^ Tatyana K (21 April 2021). "Healthcare Ministry comments on production of QazVac vaccine". www.inform.kz. Retrieved 22 April 2021.
  11. ^ "К концу апреля в Казахстане будет выпущено 50000 доз собственной вакцины" [By the end of April, 50,000 doses of its own vaccine will be released in Kazakhstan]. SNG.TODAY (in Russian). Retrieved 12 April 2021.
  12. ^ a b Kussainova M (10 April 2021). "Kazakhstan's COVID-19 vaccine to be bottled in Turkey". www.aa.com.tr. Retrieved 12 April 2021.
  13. ^ Satubaldina A (5 October 2021). "Kazakhstan to Supply Its QazVac COVID-19 Vaccine to Other Countries Next Year". The Astana Times.
  14. ^ Clinical trial number NCT04530357 for "Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine" at ClinicalTrials.gov
  15. ^ Tatyana K (9 April 2021). "3rd stage of clinical trials of QazCovid-in vaccine to be 50% complete by Apr 15". www.inform.kz. Retrieved 11 April 2021.
  16. ^ Ondiris A (9 April 2021). "Как правильно применять казахстанскую вакцину QazVac, рассказал ученый" [How to properly apply the Kazakh vaccine QazVac]. Главные новости Казахстана - Tengrinews.kz (in Russian). Retrieved 11 April 2021.
  17. ^ Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, et al. (September 2021). "Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan". eClinicalMedicine. 39: 101078. doi:10.1016/j.eclinm.2021.101078. PMC 8363482. PMID 34414368.
  18. ^ Mauletbay S (9 April 2021). "Казахстанскую вакцину QazVac будут разливать в Турции" [Kazakhstan vaccine QazVac will be bottled in Turkey]. informburo.kz (in Russian). Retrieved 12 April 2021.
edit
 
Scholia has a profile for QazCovid-in (Q99518269).
Retrieved from "https://en.wikipedia.org/w/index.php?title=QazCovid-in&oldid=1247417700"